The Brady Urological Institute has achieved world renown recognition for discoveries that led to improvements in the surgical treatment of prostate cancer.
However, not every man will benefit from treatment since some cancers will never progress to a harmful state.
Researchers at the Brady Urological Institute have a commitment to learn how to identify those men who can safely forego treatment -instead undergoing careful monitoring for any evidence of progression of their disease (active surveillance).
The active surveillance program at the Brady Urological Institute, under the direction of Dr. Ballentine Carter and Dr. Jonathan Epstein, has enrolled more than 1000 men over more than 15 years who are thought to have tumors that can be safely managed without immediate treatment.
Click here to listen to a podcast featuring Dr. H. Ballentine Carter, director of adult urology at Johns Hopkins, discussing active surveillance